Newsroom
Our latest developments
Orca Bio’s announcements and press releases
Orca Bio Presents New Data at the 2026 Tandem Meetings of ASTCT® and CIBMTR® Reinforcing Orca-T® as a Durable, High-Precision Cell Therapy for Hematological Malignancies
ViewOrca Bio to Present New Clinical Data on Its High-Precision Cell Therapies at the 2026 Tandem Meetings of ASTCT® and CIBMTR®
ViewOrca Bio Announces $250M in Aggregate Financing in Preparation for Potential Commercialization
ViewOrca Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference
ViewOrca Bio Announces Orca-T® Phase 3 Data Published in Blood Demonstrate Significant Improvement in Survival Free from Chronic Graft versus Host Disease in Patients with Hematological Malignancies
ViewOrca Bio Presents New Clinical Data on its Pipeline of High-Precision Cell Therapies including Orca-Q® Without GvHD Prophylaxis and Orca-T/CAR-T Combination Therapy at the 67th ASH Annual Meeting
ViewOrca Bio Presents New Clinical Data on Orca-T® in Older Patients Using Reduced Intensity Conditioning Plus New Analyses from the Precision-T Phase 3 Study at the 67th ASH Annual Meeting
ViewOrca Bio's fact sheets
Orca Bio Corporate Overview
View